Program Faculty
James F. Neuenschwander II, MD
Attending Emergency Physician
Genesis Healthcare System
Zanesville, OH
Dr. Neuenschwander is the Research Director and Attending Physician at the Genesis Healthcare System Emergency Department in Zanesville, Ohio.
Dr. Neuenschwander is active with research and is the primary investigator on a number of studies. He also sees patients full time in the ED, Observation Unit, Woundcare Clinic, and HBO.
He is active at the Ohio State University as an Adjunct Associate Professor with resident teaching and research collaboration.
Dr. Neuenschwander serves on the Peer Review and Antibiotic Stewardship Committees and has helped launch the Observation Unit at Genesis. He has his Medication Assisted Treatment waiver and is part of an ongoing research project determining the effectiveness of starting medications to stop opioid withdrawal with a rapid follow up to treatment.
Dr. Neuenschwander is a graduate of Case Western Reserve School of Medicine and is currently an Alumni Board member.
He completed his residency program at the Johns Hopkins Hospital in 1998. He loves to teach and participates in multiple CME programs throughout the country while still finding time to play soccer, exercise and spend time with his beautiful wife and wonderful children.
Michael R. Broyles, PharmD
Director of Pharmacy and Lab Services
Five Rivers Medical Center
Pocahontas, AR
Dr. Michael Broyles is the lab director and director of pharmacy at Five Rivers Hospital.
As a hospital pharmacy and laboratory director focusing on antimicrobial stewardship and consultant for a large IDN as pharmacy advisory chairman for more than 25 years, he is one of the pioneers in Procalcitonin utilization and brings over a decade of experience with a multitude of publications and research findings.
Mike has worked diligently for the past several years, crossing the country, educating Healthcare Representatives about Antibiotic Usage and improving patient outcomes.
He recently completed a study in which he included data from over 2100 patients that had been treated at Five Rivers Medical Center. The study consisted of comparing data that was found with the patients who were treated with antibiotics prior to the use of a laboratory test called Procalcitonin (PCT) and those that were treated after the test was available. Procalcitonin (PCT) is a Peptide Precursor of the hormone Calcitonin. The level of Procalcitonin will rise in the presence of a bacterial infection. During the course of antibiotic treatment for these bacterial infections, PCT is measured to verify that the antibiotic administered is decreasing the level of PCT found circulating in the patient’s bloodstream. If not, Antibiotics might need to be adjusted or changed. As PCT decreases, the Antibiotics are able to be discontinued earlier than if other laboratory tests are used without PCT as the Physician’s guide.
What Mike found during his study, was astounding and definitely proved that antibiotic usage has decreased due to PCT availability and use.
With decreased antibiotic use, the patient’s susceptibility to the side effects as well as other Antibiotic related sequela is vastly diminished.
Please see the resources section of this website to view links to some of the academic articles published by Dr. Broyles.
Eric H. Gluck, MD
Director of Critical Care Services
Swedish Covenant Hospital
Chicago, Illinois
Dr. Gluck received his doctoral degree in medicine from New York Medical College in Valhalla, New York.
He completed his residency at Beth Israel Medical Center in New York City and a pulmonary fellowship at the University of Utah School of Medicine in Salt Lake City, Utah. Dr. Gluck currently serves as the director of Critical Care Services at Swedish Covenant Hospital in Chicago, Illinois, and as a professor of medicine at Finch University of Health Sciences at the Chicago Medical School. He is also a fellow of the Society of Critical Care Medicine, the American College of Chest Physicians, and the Chicago Institute of Medicine and a member of the American Thoracic Society, the Society of Sigma Xi, Alpha Omega Alpha, and the American Society of Law, Medicine, and Ethics. He has delivered numerous lectures and co-authored many articles in the field of pulmonary critical care.
Dr. Gluck is renown pulmonologist that provides a snappy and straightforward approach to critically ill patients and how to manage them utilizing Procalcitonin.
His experience is vast and his contributions to understanding Procalcitonin are noteworthy, including serving as an author of the foundation for the MOSES trial, which expanded the procalcitonin FDA claim, and a member on PCT-Guided Antibiotic Therapy in Hospitals.